Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS alphavaccine
- Development stage
- Discontinued
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
SARS alphavaccine is an investigational vaccine developed by AlphaVax using its proprietary alphavaccine platform to target the coronavirus responsible for Severe Acute Respiratory Syndrome (SARS-CoV). The vaccine utilizes Viral Replicon Particles (VRPs) derived from an attenuated Venezuelan Equine Encephalitis (VEE) virus. In this system, the structural genes of the alphavirus are replaced with the gene for a SARS-specific antigen, typically the SARS coronavirus spike protein. When administered, these non-replicating RNA particles infect host cells and express the target antigen, triggering robust humoral (antibody) and cellular (T-cell) immune responses without producing new infectious viral particles. This technology is designed to combine the safety of a killed vaccine with the high immunogenicity of a live virus vaccine.
- Other names
- AlphaVax SARS vaccineSARS RNA particle vaccineVRP-SARS
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS alphavaccine.